ArticleCatheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions2025
Long-Term Follow-Up After Direct-Flow Transcatheter Aortic Valve Implantation: A Single Center Experience.
Article in Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
aimsValve degeneration after DirectFlow implantation poses a challenge for valve-in-valve procedures due to its fragile polymeric structure and embolization risk. This study analyzes long-term follow-up of patients who underwent TAVI with DF to understand valve degeneration tendencies.
methodsIn this single-center registry, we included all patients who underwent DF implantation in our center. Clinical characteristics and echocardiographic parameters were assessed at baseline and during the latest follow-up. Long-term overall survival was analyzed. Outcome data was compared with a matched cohort of patients who underwent TAVI with other commercial devices during the same period.
resultsFrom 2014 to 2017, 67 patients with significant aortic stenosis were treated with DF; 36 (54%) were male, mean age 83 ± 7 years. Left ventricular ejection fraction was 50 ± 13% with a mean gradient of 46 ± 15 mmHg. Post-procedural echocardiography showed a mean gradient of 16 ± 8 mmHg, markedly higher than the reference group (8 ± 3 mmHg; p < 0.01). This residual gradient showed no progression during follow-up at 20 [9; 39] months (16 ± 9 mmHg; p = 0.52). Overall survival was comparable between DF and the reference group at 12 months (6% vs. 4%, HR 1.37, 95% CI 0.31-6.02) and maximal follow-up of 39 ± 25 months (31% vs. 25%, HR 1.44, 95% CI 0.76-2.73).
conclusionsAccording to this single center experience, DF devices resulted in higher residual gradients; however, no signs of faster degeneration or worse long-term outcomes were observed compared to other devices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.